Recent update on cisplatin induced acute kidney injury

Journal of Internal Medicine of Taiwan

Volumn 22, Issue 6, 2011, Pages 416-422

  Lin, You Hsien ^a,b   Lin, Sheng Fung ^a   Hsiao, Hui Hua ^a   Liu, Yi Chang ^a   Yang, Wen Chi ^a   Hwang, Daw Yang ^a   Hung, Chi Chih ^a   Hwang, Sang Jyh ^a   Guh, Jinn Yuh ^a   Chen, Hung Chun ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ACUTE KIDNEY FAILURE; ARTICLE;

EID: 84863372273     PISSN: 10167390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965;205: 698-9.
2. Wang D, Lippard S. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4: 307-20. (Pubitemid 41130944)
3. Arany I, Safirstein R. Cisplatin nephrotoxicity. Semin Nephrol 2003; 23: 460-64. (Pubitemid 37176691)
4. Cohen SM, Lippard S. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 2001; 67: 93-130. (Pubitemid 33804642)
5. Siddik, ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22:7265-79. (Pubitemid 37487159)
6. Ciccarelli RB, Solomon M, Varshavsky A, et al. In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry 1985; 24: 7533-40. (Pubitemid 16140484)
7. Zamble DB, Lippard S. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995;20: 435-9.
8. Jamieson ER, Lippard S. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999; 99: 2467-98.
9. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol 1987; 34: 155-66. (Pubitemid 17149009)
10. Pasetto LM, D'Andrea MR, Brandes AA, et al. The development of platinum compounds and their possible combination. Crit Rev Oncol Hematol 2006; 60: 59-75. (Pubitemid 44404105)
11. Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 1993; 50: 147-58. (Pubitemid 23275196)
12. Bajorin DF, Bosl G, Alcock NW, et al. Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline. Cancer Res 1986; 46: 5969-72. (Pubitemid 17178013)
13. Beyer J, Rick O, Weinknecht S, et al. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome. Bone Marrow Transplant 1997; 20: 813-9. (Pubitemid 27493917)
14. Hill JM, Speer R. Organo-platinum complexes as antitumor agents. Anticancer Res 1982; 2:173-186.
15. Beyer J, Rick O, Weinknecht S, et al. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome. Bone Marrow Transplant 1997; 20: 813-9. (Pubitemid 27493917)
16. Pabla N, Dong Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney International 2008; 73: 994-1007. (Pubitemid 351543900)
17. Ludwig T, Riethmüller C, Gekle M, et al. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int 2004; 66: 196-202. (Pubitemid 38870095)
18. Yonezawa A, Masuda S, Nishihara K, et al. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol 2005; 70: 1823-31. (Pubitemid 41612013)
19. Motohashi H, Sakurai Y, Saito H, et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 2002; 13:866-74. (Pubitemid 34274082)
20. Ciarimboli G, Ludwig T, Lang D, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 2005; 167: 1477-84. (Pubitemid 41713303)
21. Townsend DM, Deng M, Zhang L, et al. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 2003; 14: 1-10. (Pubitemid 36026291)
22. Hanigan MH, Gallagher B, Taylor PT Jr, et al. Inhibition of gammaglutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity. Cancer Res 1994; 54: 5925-29.
23. Hanigan MH, Lykissa E, Townsend DM, et al. Gamma-glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin. Am J Pathol 2001; 159: 1889-94. (Pubitemid 33062530)
24. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008; 73: 994-1007. (Pubitemid 351543900)
25. Lieberthal W, Triaca V, Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol 1996; 270: F700-8.
26. Faubel S, Ljubanovic D, Reznikov L, et al. Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int 2004; 66: 2202-13. (Pubitemid 41115283)
27. Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 2005; 289: F166-74. (Pubitemid 40863584)
28. Li S, Basnakian A, Bhatt R, et al. PPAR-alpha ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G. Am J Physiol Renal Physiol 2004; 287: F990-8. (Pubitemid 39391096)
29. Megyesi J, Safirstein R, Price PM. Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J Clin Invest 1998; 101: 777-82. (Pubitemid 28096074)
30. Tsuruya K, Ninomiya T, Tokumoto M, et al. Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int 2003; 63: 72-82. (Pubitemid 35463908)
31. Wei Q, Dong G, Franklin J, et al. The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int 2007; 72: 53-62. (Pubitemid 47014446)
32. Dursun B, He Z, Somerset H, et al. Caspases and calpain are independent mediators of cisplatin-induced endothelial cell necrosis. Am J Physiol Renal Physiol 2006; 291: F578-87. (Pubitemid 44343739)
33. Strasser A, O'Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem 2000; 69: 217-45.
34. Ramesh G, Reeves W. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002; 110: 835-42.
35. Ramesh G, Reeves W. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 2003; 285: F610-8. (Pubitemid 37140245)
36. Danial NN, Korsmeyer S. Cell death: critical control points. Cell 2004; 116: 205-19. (Pubitemid 38167313)
37. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-12. (Pubitemid 28406816)
38. Jiang M, Yi X, Hsu S, et al. Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity. Am J Physiol Renal Physiol 2004; 287: F1140-7. (Pubitemid 39507222)
39. Jiang M, Wei Q, Wang J, et al. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene 2006; 25: 4056-66. (Pubitemid 44024868)
40. Nagothu KK, Bhatt R, Kaushel GP, et al. Kaushal GP, et al. Fibrate prevents cisplatin-induced proximal tubule cell death. Kidney Int 2005; 68: 2680-93. (Pubitemid 43251013)
41. Wangila GW, Nagothu K, Steward III R, et al. Prevention of cisplatin-induced kidney epithelial cell apoptosis with a Cu superoxide dismutase-mimetic [copper2II(3,5-ditertiarybutyl salicylate)4(ethanol)4]. Toxicol In vitro 2006; 20: 1300-12.
42. Jiang M, Wei Q, Pabla N, et al. Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol 2007; 73: 1499-510. (Pubitemid 46452592)
43. Wang J, Wei Q, Wang CY, et al. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem 2004; 279: 19948-54. (Pubitemid 38623437)
44. Boyce M, Yuan J. Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Differ 2006; 13: 363-73.
45. Cummings BS, Schnellmann R. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and-independent pathways. J Pharmacol Exp Ther 2002; 302: 8-17. (Pubitemid 34680415)
46. Owens DM, Keyse S. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 2007; 26: 3203-13. (Pubitemid 46763015)
47. Dhillon AS, Hagan S, Rath O, et al. MAP kinase signalling pathways in cancer. Oncogene 2007; 26: 3279-90. (Pubitemid 46763021)
48. Weijl NI, Elsendoorn T, Lentjes EG, et al. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer 2004; 40: 1713-23. (Pubitemid 38902907)
49. Deng J, Kohda Y, Chiao H, et al. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 2001; 60: 2118-28. (Pubitemid 33070455)
50. Ferguson MA, Vaidya V, Bonventre JV. Biomarkers of nephrotoxic acute kidney injury. Toxicology 2008; 245: 182-93.
51. MB, Myers S. Course of acute renal failure studied by a model of creatinine kinetics. Kidney Int 1985; 27: 982-37.
52. Star RA. Treatment of acute renal failure. Kidney Int 1998; 54: 1817-31. (Pubitemid 28533609)
53. Han WK, Bailly V, Abichandani R, et al. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002; 62: 237-44. (Pubitemid 34754067)
54. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365: 1231-8. (Pubitemid 40469655)
55. Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol 2005; 16: 3046-52. (Pubitemid 44743502)
56. Herget-Rosenthal S, Marggraf G, Husing J, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004; 66: 1115-22. (Pubitemid 39121017)
57. Doi K, Noiri E, Sugaya T. Urinary L-type fatty acid-binding protein as a new renal biomarker in critical care. Curr Opin Crit Care 2010; 8: 545-9.
58. Han WK, Walker SS, Johnson A, et al. Urinary biomarkers for detection of acute kidney injury. Kidney Int 2007; 73: 863-9.
59. Mishra J, Mori K, Ma Q, et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2004; 15: 3073-82. (Pubitemid 39578839)
60. Devarajan, P. Review: neutrophil gelatinase-associated lipocalin: a troponin-like biomarker for human acute kidney injury. Nephhrology 2010; 15: 419-28.
61. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel urinary biomarker for ischemic injury. J Am Soc Nephrol 2003; 4: 2534-43. (Pubitemid 37169339)
62. Mishra J, Mori K, Ma Q, et al. Neutrophil Gelatinase-Associated Lipocalin (NGAL): A novel urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004;24: 307-15. (Pubitemid 39070114)
63. Mori K, Lee H, Rapoport D, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney fromischemia-reperfusion injury. J Clin Invest 2005; 115: 610-21. (Pubitemid 40322235)
64. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury following cardiac surgery. Lancet 2005; 365: 1231-8. (Pubitemid 40469655)
65. Parikh CR, Mishra J, Thiessen-Philbrook H, et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int 2006; 70: 199-203. (Pubitemid 44000139)
66. Portilla D, Dent C, Sugaya T, et al. Liver Fatty Acid-Binding Protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int 2008; 73: 465-72. (Pubitemid 351186293)
67. Mishra J, Mori Q, Kelly C, et al. Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol 2006; 21: 856-63. (Pubitemid 43740956)
68. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, et al. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol 2006; 26: 287-92. (Pubitemid 44121091)
69. Niemann CU, Walia A, Waldman J, et al. Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin. Liver Transplant 2009; 15: 1852-60.
70. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004; 24: 307-15. (Pubitemid 39070114)
71. Gaspari F, Cravedi P, Mario Mandalà, et al. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase- associated lipocalin excretion: a pilot prospective case-control study. Nephron Clin Pract 2010; 115: c154-c60.
72. Benöhr P, Grenz A, Hartmann JT, Müller GA, Blaschke S. Cystatin C - a marker for assessment of the glomerular filtration rate in patients with cisplatin chemotherapy. Kidney Blood Press Res 2006; 29: 32-5. (Pubitemid 43875170)